Crinetics Pharmaceuticals, Inc.
CRNX
$84.70
$0.260.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 134.00% | 74.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 134.00% | 74.22% | |||
| Cost of Revenue | -0.28% | 16.43% | |||
| Gross Profit | 16.37% | -11.98% | |||
| SG&A Expenses | 13.26% | -5.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.28% | 8.07% | |||
| Operating Income | 5.64% | -5.02% | |||
| Income Before Tax | 5.47% | -4.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.47% | -4.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.47% | -4.10% | |||
| EBIT | 5.64% | -5.02% | |||
| EBITDA | 5.63% | -4.93% | |||
| EPS Basic | 6.77% | 4.91% | |||
| Normalized Basic EPS | 6.77% | 4.76% | |||
| EPS Diluted | 6.77% | 4.91% | |||
| Normalized Diluted EPS | 6.77% | 4.76% | |||
| Average Basic Shares Outstanding | 1.40% | 9.47% | |||
| Average Diluted Shares Outstanding | 1.40% | 9.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||